Arlington Trust’s Genmab GMAB Stock Holding History

Arlington Trust’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$856	Hold	24	–	–	﹤0.01%	853
2026 Q2	$659	Hold	24	–	–	﹤0.01%	767
2026 Q1	$644	Buy	+24	New	+$719	﹤0.01%	758

Other funds holding GMAB

Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Legacy Wealth Asset Management Woodbury, Minnesota $456M AUM 31.62% 1-Year Est. Return

Terra Nova Asset Management New York $155M AUM 33.52% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Quadrant Capital Group Cincinnati, Ohio $3.7B AUM 33.76% 1-Year Est. Return

Evergreen Capital Management Bellevue, Washington $5.65B AUM 21.62% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Arlington Trust's GMAB Position: Q3 2026 in Review

Arlington Trust held its Genmab (GMAB) position steady in Q3 2026 at 24 shares worth $856. The position accounts for ﹤0.01% of the portfolio, ranked #853.

Arlington Trust first reported a position in GMAB in Q1 2026 and has held it in 3 quarters since. 58 funds tracked by Wall St. Rank hold GMAB as of Q3 2026.

Arlington Trust held 24 shares of Genmab worth $856 as of Q3 2026.
Arlington Trust left its Genmab share count unchanged in Q3 2026.
Genmab made up ﹤0.01% of Arlington Trust's portfolio in Q3 2026, its #853 holding.
Arlington Trust first reported a position in Genmab in Q1 2026 and has held it in 3 quarters since.
58 funds tracked by Wall St. Rank held Genmab as of Q3 2026.

Based on Arlington Trust's 13F filing for Q3 2026, filed 20 Oct 2026.